Thermo Fisher Scientific acknowledges the value of supporting independent research projects in order to promote excellence in molecular diagnostics.
The Oncomine Clinical Research Grant Program is currently accepting proposals addressing unmet diagnostic needs using next-generation sequencing for both solid and hematological cancers. Studies aiming to demonstrate the value of fast complete molecular diagnostics are warmly welcome, equally as projects addressing needs in pediatric cancers.
Grant submissions are open from APRIL 14 - JUNE 16, 2023.
To expand opportunity and offer all research teams the chance to participate, our call for Spring 2023 proposals to the Oncomine Clinical Research Grant Program has been extended to June 16th.
Grant Focus Area:
Cancer Genomic Profiling
Proposals will be accepted through the submission portal. Alternatively we may accept via the email firstname.lastname@example.org. Please visit this web page during the open submission period to submit your application.”
Read our blog for tips on how to submit a strong grant application.
The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular profiling in oncology, with the goal to increase high quality molecular profiling and to help democratize the future of precision medicine.
Proposal reviews are conducted by independent and internationally recognized experts together with Thermo Fisher Scientific medical and scientific leadership. Funding is considered based on scientific merit.
The application process is managed by the Oncomine Clinical Research Grant Office, part of the Medical Affairs team of the Clinical Sequencing Division at Thermo Fisher Scientific. For detailed information about how to apply, including documentation requirements, review process, and decision notification, refer to the Guidelines for Applicants.
Grant applications should be submitted electronically (English only) using the specific Proposal Form. Proposals should outline the planned activities to be performed within a maximum of 12 months. A budget is required for every grant request and should detail the proposed use of requested funds. The maximum budget request for each project is set at $200,000.
We thank all applicants that submitted projects across our 2022 calls for applications.
We are pleased to announce the 2022 grant awardees below.
“Mutational Analysis of Bile cfDNA for the Early Diagnosis of Biliopancreatic Tumors”
“Genomic Profiling and Disease Monitoring Using Plasma Cell-Free DNA in Acute Myeloid Leukemia”
“ctDNA Analysis to Understand Resistance and Response to ORC Therapy in EGFR Mutant Non-Small Cell Lung Cancer”
“Liquid Biopsy in Suspected Lung Cancer Solitary Pulmonary Nodules”
“Molecular measurable residual disease (MRD) monitoring by high-throughput techniques in patients with CART 19 therapy”
“HRD biomarker: Qualification and implementation of validated local HRD test”
“Comprehensive molecular characterization of early stage NSCLC with KRAS G12C mutation using ODxET”
For any questions about the Oncomine Clinical Research Grant Program, please email email@example.com